drugset / Trial / NCT05343312

In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique

NCT05343312

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a classical in vivo clinical trial, following World Health organization's recommendations, ran as a multisite study within Mozambique trying to assess the efficacy and safety in 5 sites of the four oral ACTS artemether-lumefantrine (AL), Amodiaquine-Artesunate (AQ-AS), Dihydroartemisinin-Piperaquine (DHP) and Pironaridine-Artesunate for the treatment of uncomplicated malaria in children aged\<5 years.

Timeline

Start
2022-03-16
Primary completion
2023-09-30
Completion
2025-07-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator ARTENIMOL Small molecule 20 mg Oral
Comparator ARTENIMOL Small molecule 40 mg Oral
Comparator ARTENIMOL Small molecule 80 mg Oral
Comparator Artemether Small molecule 20 mg Oral
Comparator Artemether Small molecule 40 mg Oral
Comparator Artemether Small molecule 60 mg Oral
Comparator Artesunate Small molecule 20 mg Oral
Comparator Artesunate Small molecule 25 mg Oral
Comparator Artesunate Small molecule 40 mg Oral
Comparator Artesunate Small molecule 50 mg Oral
Comparator Artesunate Small molecule 60 mg Oral
Comparator Artesunate Small molecule 100 mg Oral
Comparator Artesunate Small molecule 120 mg Oral
Comparator Pyronaridine Unknown 60 mg Oral
Comparator Pyronaridine Unknown 120 mg Oral
Comparator Pyronaridine Unknown 180 mg Oral
Comparator Pyronaridine Unknown 360 mg Oral
Comparator amodiaquine Other / unclassified 67.5 mg Oral
Comparator amodiaquine Other / unclassified 135 mg Oral
Comparator amodiaquine Other / unclassified 270 mg Oral
Comparator lumefantrine Small molecule 120 mg Oral
Comparator lumefantrine Small molecule 240 mg Oral
Comparator lumefantrine Small molecule 360 mg Oral
Comparator piperaquine Small molecule 160 mg Oral
Comparator piperaquine Small molecule 320 mg Oral
Comparator piperaquine Small molecule 640 mg Oral